Haploidentical Donors and Posttransplant Cyclophosphamide Comparable to Preferred Matched Sibling Donor Type in Myelofibrosis
Data comparing 4 donor types showed matched sibling donors to be preferred in patients with myelofibrosis, according to a presentation given at the 2023 Transplantation and Cellular Therapy Meeting.
Tania Jain, MD, MBBS
When available, matched sibling donors (MSD) are the preferred donor for patients with myelofibrosis. However, for patients lacking MSD, utilizing haploidentical donors (HD) and posttransplant cyclophosphamide (PTCy) is a similar option to unrelated donors for blood or marrow transplantation (BMT) in this space.
In a presentation at the 2023 Transplantation and Cellular Therapy Meeting, Tania Jain, MD, of Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discussed data from a study which aimed to compare outcomes of 4 common donor types when using HD-PTCy.
Previously, registry data that came out prior to the emergence of HD have shown the superiority of MSD compared with matched unrelated (MUD) donors in treating patients with myelofibrosis. With BMT using HD and PTCy (HD-PTCy) in myelofibrosis, a multi-center study then led to an overall survival (OS) rate of 72% in patients and a disease-free survival (DFS) of 44% at 3 years.
To further evaluate the unknown outcomes of the 4 donor types, HD-PTCy, MSD, MUD and mismatched unrelated donor (MMUD), experts reviewed data from CIBMTR, which is a working group of over 500 BMT centers. Investigators obtained data from 1,057 adult patients who underwent a first BMT using peripheral blood graft between 2013-2019 for chronic phase myelofibrosis (<10% blasts) using HD-PTCy, MSD, MUD and MMUD.
Across the 4 donor groups, standard univariate and multivariate analyses were conducted for comparison. In the multivariate analysis, control variables included age, gender, race and ethnicity, sub-diagnosis, time from diagnosis to BMT, dynamic international prognostic scoring system (DIPSS) at BMT, prior use of JAK inhibitors, splenomegaly at BMT, donor-recipient sex match and CMV status, conditioning intensity, and year of BMT.
"Haploidentical donor BMT outcomes are comparable to matched unrelated donor BMT. Over the years, haplo donors have been used for non-White population. Relapse rates overall are high and better pre-BMT spleen size reduction may be worth exploring to improve relapse rates following BMT," Jain, told Targeted OncologyTM discussing the outcomes of this analysis. "Matched sibling donors had a lower NRM and lower graft failure rates. This almost exclusively accounts for better overall survival with matched sibling donors, which only holds significance in the first 3 months. While graft failure rates with haplo donors were higher, we need to identify risk factors associated with lower engraftment to improve success of BMT overall."
In the study, HD was defined as a family donor mismatched by 2 or more HLA loci, MUD was defined as matched at allele level HLA-A, -B, -C, and -DRB1, and MMUD as unrelated and mismatched by 2 or more HLA loci.
The study excluded patients who underwent BMT using cord blood graft or T-cell depletion.
Among the 1057 patients enrolled, 121 were HD, 312 were MSD, 547 were MUD, and 68 were MMUD. Across donor types of HD vs MSD vs MUD vs MMUD, a majority of patients were male (60% vs 59% vs 57% vs 59%), White (60% vs 80% vs 90% vs 76%) and had a sub-diagnosis of primary myelofibrosis (70% vs 67% vs 69% vs 72%).
Baseline characteristics showed that the median age for HD to be 63 years (range, 34-75), 61 (range, 34-75) for MSD, 63 (range, 32-78) for MUD, and 60 (range, 38-72) for MMUD. The median time from diagnosis to BMT was 34 months (2-401), 28 months (2-417), 29 months (2-522), and 31 months (4-363) for HD, MSD, MUD, and MMUD, respectively. Across all donor groups, 26%, 47%, 44%, and 46% received myeloablative conditioning while 72%, 50%, 55%, and 53% received non-myeloablative conditioning in the HD, MSD, MUD, and MMUD groups, respectively.
The median follow-up in the HD group was 36 months (range, 9-77), 46 months (range 13-100) for MSD, 48 months (range, 4-98) for MUD, and 49 months (range, 23-98) for the MMUD donor type.
Univariate 3-year estimate for OS was 58% for HD (49%-57%), 68.3% for MSD (63%-74%), 61.5% for MUD (57%-66%), and 57.9% for MMUD (46%-70%) for a P value of .044. At 1-year, primary graft failure was at 19% for HD, 4% for MSD, 8% for MUD, and 6% for MMUD (P < .001).
For DFS, rates were 28%, 31%, 27%, and 29% (P = .21), relapse was 44%, 52%, 48%, and 44% (P = .68), and non-relapse mortality (NRM) was 27%, 17%, 25%, and 28% (P = .03), for HD, MSD, MUD, and MMUD, respectively.
Rates of grade 3-4 acute graft vs host (GVHD) disease at 3 years were 16% for HD, 24% for MSD, 18% for MUD, and 28% for MMUD (P = .05). Chronic GVHD rates at 3 years were 42%, 57%, 52%, and 50%, respectively (P = .07).
"[We need more] identification of maintenance post-BMT to address relapse, and to explore pre-BMT strategies to improve spleen size and marrow fibrosis with an aim to improve relapse and engraftment. Early referral for BMT is critical in this disease and consideration/referral for BMT for all patients must be made by referring doctors to determine the appropriate timing and risk factors for BMT. The role of next generation sequencing in the BMT outcomes needs to be explored further," Jain explained.
In the multivariate analysis, the OS at 3 months or less from BMT was superior with MSD vs HD-PTCy (HR, 0.22; 95% CI, 0.11-0.46; P < .0001) compared with MSD (HR, 0.30; 95% CI, 0.17-0.53; P < .0001) vs MMUD (HR, 0.28; 95% CI, 0.09-0.93; P = .04). This was largely attributed to lower NRM with the use of MSD.
After the first 3 months, the OS did not significantly differ between HD-PTCy, MUD, or MMUD. After 3 months post BMT, NRM, relapse, or DFS, there was also no statistically significant difference between the 4 donor types.
Looking at NRM in the multivariate analysis, the rate was superior with MSD vs MUD (HR, 0.69; 95% CI, 0.50-0.94; P = .02), and vs MMUD (HR, 0.28; 95% CI, 0.09-0.93; P = .04). Rates were also superior compared with MUD vs MMUD (HR, 0.94; 95% CI, 0.38-2.31; P = .89).
Though MSD is the preferred donor in patients with myelofibrosis, HD-PTCy has shown to be a similar option to unrelated donors for BMT for patients who lack MSD. Overall, these data highlight the need to reduce early NRM and long-term relapse rates in this diagnosis, conlcuded Jain.
